Alveolar Ridge DeficiencyNCT07701473
Novel Synthetic Membrane for Horizontal Bone Augmentation: A Case Series
A study testing Inox Nanoksa G-Plus Membrane and Particulate Bone Graft in people with Alveolar Ridge Deficiency and Alveolar Bone Loss, run by Cairo University at 1 site in Egypt.
Trial summary
The goal of this clinical study is to learn if the Inox Nanoksa G-Plus membrane works to rebuild bone in the upper or lower jaw (ridge augmentation) for adults who need dental implants but do not have enough bone width or height. It will also learn about the safety of this membrane and how patients feel after surgery. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Alveolar Ridge Deficiency, Alveolar Bone Loss
- What is being tested?
- Inox Nanoksa G-Plus Membrane and Particulate Bone Graft
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 12 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Sep 2026to 1 Sep 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Partial edentulism in the maxilla or mandible requiring single or multiple implant-supported restorations.
- Insufficient bone volume for standard implant placement, defined as:
- Horizontal defect: residual ridge width < 5 mm at the intended implant site, OR
- Vertical defect: residual ridge height < 8 mm above vital structures (mandibular canal, maxillary sinus, nasal floor).
- Healthy oral mucosa with no signs of active infection or inflammation at the defect site.
- Systemically healthy or with well-controlled medical conditions (American Society of Anesthesiologists - ASA class I or II).
Who cannot join
- Untreated periodontitis or active peri-implant disease.
- Current or previous treatment with intravenous bisphosphonates (or oral bisphosphonates for > 3 years).
- Severe immunosuppression or chronic systemic corticosteroid therapy (> 10 mg/day prednisolone for > 3 months).
- Active smoking (> 10 cigarettes per day). Smoking cessation for at least 2 weeks before surgery is required; heavy smokers may be excluded.
- Pregnant or lactating women.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Egypt1 site
Department of Periodontics, Faculty of Dentistry, Cairo University
Cairo, Cairo Governorate, 11553
Olfat H. Olfat Hassanein, +20223642705, rec@dentistry.cu.edu.eg
About this study
Official title: Efficacy of a Novel Synthetic GBR Membrane (Inox Nanoksa G-Plus) for Horizontal Ridge Augmentation: A Case Series
The goal of this clinical study is to learn if the Inox Nanoksa G-Plus membrane works to rebuild bone in the upper or lower jaw (ridge augmentation) for adults who need dental implants but do not have enough bone width or height. It will also learn about the safety of this membrane and how patients feel after surgery.
- The main questions it aims to answer are: How much pain, swelling, and bleeding do participants experience during the first week after the bone-building surgery? How much new bone width and height does the membrane help grow, as measured on a 3D X-ray (CBCT) taken 6 months after surgery? What medical problems or side effects (such as the membrane becoming visible through the gums, infection, or graft loss) do participants experience? This is a single-treatment study; all participants will receive the same surgery using the Inox Nanoksa G-Plus membrane together with a bone graft material.
Read more
Participants will:
Have surgery to place the membrane and bone graft under their gums to rebuild their jawbone.
Take antibiotics and pain relievers, and use a special mouth rinse for about 2 weeks after surgery.
Rate their pain, swelling, and bleeding on simple scales on days 1, 3, and 7 after surgery.
Return for a checkup at 1 month and have a follow-up 3D X-ray at 6 months. Undergo a second surgery at 6 months to have dental implants placed and to evaluate the newly formed bone.
Read the detailed description
Alveolar ridge resorption following tooth loss frequently results in insufficient bone width or height for ideal dental implant placement, affecting more than 40% of patients seeking implant therapy. Guided Bone Regeneration (GBR) is a well-established surgical technique for reconstructing these deficient ridges using barrier membranes. However, existing membranes present significant limitations: non-resorbable expanded polytetrafluoroethylene (e-PTFE) membranes require a second surgery for removal and carry high exposure-related complication rates, while resorbable collagen membranes often lack adequate mechanical stability and degrade unpredictably, particularly in vertical or large horizontal defects.
The Inox Nanoksa G-Plus membrane is a novel, non-resorbable hybrid nano-ceramic material containing nano-carbon and nano-zirconia within a methacrylate-based high-performance polymer matrix. While the manufacturer claims high strength, wear resistance, and biocompatibility for prosthetic applications, and recent in vitro studies have characterized its mechanical properties, no published clinical study has evaluated its safety or efficacy as a barrier scaffold for GBR in human patients. This knowledge gap forms the basis for the present investigation.
This study is designed as a prospective, single-arm, interventional clinical trial conducted at the Department of Periodontics, Faculty of Dentistry, Cairo University. No randomization or comparator group is included, as this is an initial clinical evaluation of a novel device. All eligible and consenting participants will receive the same standardized intervention.
Study Population: Systemically healthy adult patients (ASA class I or II), aged 18 years or older, presenting with partial edentulism in the maxilla or mandible and requiring horizontal (residual ridge width < 5 mm) or vertical (residual ridge height < 8 mm above vital structures) ridge augmentation prior to dental implant placement. Key exclusions include untreated periodontitis, bisphosphonate therapy, heavy active smoking (>10 cigarettes/day), and pregnancy or lactation.
Intervention: Participants will undergo a single GBR procedure using the Inox Nanoksa G-Plus membrane. The standardized surgical protocol involves a mid-crestal incision with full-thickness flap elevation, cortical perforations to enhance vascularization, placement of a particulate bone graft to fill the defect, and trimming and adaptation of the membrane to extend 3-5 mm beyond the defect margins. The membrane will be secured with titanium micro-screws, and the flap will be closed primarily with a tension-free, double-layer suture technique to achieve complete membrane coverage. Post-operatively, participants will receive prophylactic antibiotics (5-7 days), analgesics, and chlorhexidine mouth rinses for 14 days. Sutures will be removed at 10-14 days.
Study Assessments and Timeline: Participants will be followed for a total of 12 months after implant loading. The primary outcomes (patient-reported) include postoperative pain assessed via a Visual Analog Scale (VAS 0-10), as well as clinical grading of edema and bleeding, recorded on days 1, 3, and 7 post-surgery. Secondary outcomes are assessed clinically and radiographically: membrane exposure (scored 0-3 with descriptive details), infection, graft complications, and radiographic bone gain measured by Cone Beam Computed Tomography (CBCT) at 6 months post-GBR. Horizontal and vertical bone gains will be quantified in millimeters, and new bone density will be measured in Hounsfield Units (HU). At the 6-month re-entry surgery, the membrane and fixation screws will be removed, dental implants will be placed, and implant primary stability will be recorded. A final follow-up at 12 months after implant loading will evaluate implant survival and success.
Data Management and Analysis: All data will be recorded in standardized case report forms and entered into a password-protected electronic database. Statistical analysis will be performed using Medcalc software. Continuous variables will be analyzed using paired t-tests or Wilcoxon signed-rank tests for pre- versus post-operative comparisons, and repeated measures ANOVA for multiple time points. Categorical data will be presented as frequencies and percentages. A p-value ≤ 0.05 will be considered statistically significant. The sample size of 12 participants was calculated to estimate the mean bone gain with adequate precision, accounting for an anticipated 20% dropout rate.
Ethics and Dissemination: The study protocol has received ethical approval from the Research Ethics Committee of the Faculty of Oral and Dental Medicine, Cairo University. All participants will provide written informed consent in Arabic after receiving a full explanation of the procedures, benefits, risks, and alternative treatments. Participant confidentiality will be strictly maintained. The results of this study will be submitted for publication in a peer-reviewed dental journal and presented at academic conferences, regardless of the outcome direction, to contribute evidence on the clinical applicability of synthetic high-performance polymer membranes in bone regeneration.
- Conditions
- Alveolar Ridge Deficiency, Alveolar Bone Loss
- Being tested
- Inox Nanoksa G-Plus Membrane, Particulate Bone Graft
- Keywords
- Alveolar Ridge Augmentation, Guided Bone Regeneration, Membranes, Artificial, Bone Transplantation, GBR Membrane, Synthetic Membrane, Inox Nanoksa G-Plus, Vertical Bone Defect, Dental Implant
- Medical subject headings
- Alveolar Bone Loss
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Inox Nanoksa G-Plus MembraneDevice
A sterile, non-resorbable hybrid nano-ceramic membrane composed of a methacrylate-based high-performance polymer matrix reinforced with nano-zirconia and nano-carbon. It is supplied as a pre-formed sheet (thickness ~0.2-0.3 mm) that can be cut and shaped intraoperatively. The membrane serves as a barrier scaffold to exclude soft tissue cells and allow osteogenic cells to populate the bone defect during guided bone regeneration.
Particulate Bone GraftDevice
A commercially available particulate bone graft material (xenograft, allograft, or synthetic) selected based on defect type and surgeon preference. The graft is hydrated with sterile saline or autologous blood and packed into the defect to fill the volume and provide a scaffold for new bone formation.
| Study group | Role | What they receive |
|---|---|---|
| Nanoksa G-Plus GBR Group | Experimental | Participants with horizontal or vertical alveolar ridge deficiency undergo guided bone regeneration using the Inox Nanoksa G-Plus membrane in conjunction with a particulate bone graft. All participants receive the same standardized surgical protocol. Receives: Device: Inox Nanoksa G-Plus Membrane; Device: Particulate Bone Graft |
What is being measured
The primary outcome is the main question the study is designed to answer.
Postoperative Pain
Pain intensity measured using a Visual Analog Scale (VAS) where 0 = no pain and 10 = worst imaginable pain. Patients record pain at rest and during function.
Measured: Days 1, 3, and 7 post-surgery
Postoperative Edema/Swelling
Clinically graded by a blinded assessor using a 4-point scale: 0 = none, 1 = mild (localized, intraoral only), 2 = moderate (visible extraoral swelling, no functional impairment), 3 = severe (significant facial swelling with functional impairment).
Measured: Days 1, 3, and 7 post-surgery
Postoperative Bleeding
Clinically assessed at the surgical site using a 4-point scale: 0 = none, 1 = mild (oozing, stops spontaneously), 2 = moderate (requires gauze change or local pressure), 3 = severe (requires surgical intervention).
Measured: Days 1, 3, and 7 post-surgery
Secondary outcomes (5)
Horizontal Bone Gain
Change in ridge width measured on CBCT at 6 months compared to baseline. Measured at 1 mm, 3 mm, and 5 mm apical to the ridge crest; the mean of these three measurements is used. Gain = (width at T2) - (width at T0).
Measured: 6 months post-GBR (T2) vs. Baseline (T0)
Vertical Bone Gain
Change in ridge height measured on CBCT at 6 months compared to baseline. Measured from the crest to the most apical point of the defect in the center of the defect. Gain = (height at T2) - (height at T0).
Measured: 6 months post-GBR (T2) vs. Baseline (T0)
Membrane Exposure
Visible exposure of the Nanoksa G-Plus membrane through the oral mucosa during healing. Scored as: 0 = none, 1 = pinpoint < 2 mm no suppuration, 2 = partial 2-5 mm with/without mild inflammation, 3 = complete > 5 mm OR any exposure with suppuration/infection/graft loss. Time of first exposure and management are also recorded.
Measured: Throughout healing period (up to 6 months post-GBR)
New Bone Density
Bone density measured by CBCT densitometry in Hounsfield Units (HU) at the augmented site at 6 months compared to baseline.
Measured: 6 months post-GBR (T2) vs. Baseline (T0)
Patient Satisfaction
Overall treatment experience assessed using a Likert scale (1-5).
Measured: 6 months post-GBR (T2)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Jul 2026
- Study start1 Sep 2026 (estimated)
- Primary completion1 Mar 2027 (estimated)
- Study completion1 Sep 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Alveolar Ridge DeficiencyStudies of the same condition, open and under way.
- More trials run by Cairo UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- All participants receive the same GBR procedure using the Inox Nanoksa G-Plus membrane.
- Masking
- None (open label)
- Enrolment
- 12 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Cairo University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Hazem Ahmed, Cairo University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07701473
- Sponsor's protocol ID
- CU 7.7.2026
- Status last verified
- Jul 2026
- First submitted
- 8 Jul 2026
- Last updated
- 14 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Efficacy of a Novel Synthetic GBR Membrane (Inox Nanoksa G-Plus) for Horizontal Ridge Augmentation: A Case Series
- ClinicalTrials.gov ID
- NCT07701473
- Acronym / sponsor ID
- CU 7.7.2026
- Conditions
- Alveolar Ridge Deficiency, Alveolar Bone Loss
- Keywords
- Alveolar Ridge Augmentation, Guided Bone Regeneration, Membranes, Artificial, Bone Transplantation, GBR Membrane, Synthetic Membrane, Inox Nanoksa G-Plus, Vertical Bone Defect
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 12 participants (estimated)
- Lead sponsor
- Cairo UniversityUniversity, hospital or other
- Study start
- 1 Sep 2026 (estimated)
- Primary completion
- 1 Mar 2027 (estimated)
- Study completion
- 1 Sep 2027 (estimated)
- First posted
- 14 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical study is to learn if the Inox Nanoksa G-Plus membrane works to rebuild bone in the upper or lower jaw (ridge augmentation) for adults who need dental implants but do not have enough bone width or height. It will also learn about the safety of this membrane and how patients feel after surgery.
- The main questions it aims to answer are: How much pain, swelling, and bleeding do participants experience during the first week after the bone-building surgery? How much new bone width and height does the membrane help grow, as measured on a 3D X-ray (CBCT) taken 6 months after surgery? What medical problems or side effects (such as the membrane becoming visible through the gums, infection, or graft loss) do participants experience? This is a single-treatment study; all participants will receive the same surgery using the Inox Nanoksa G-Plus membrane together with a bone graft material.
Participants will:
Have surgery to place the membrane and bone graft under their gums to rebuild their jawbone.
Take antibiotics and pain relievers, and use a special mouth rinse for about 2 weeks after surgery.
Rate their pain, swelling, and bleeding on simple scales on days 1, 3, and 7 after surgery.
Return for a checkup at 1 month and have a follow-up 3D X-ray at 6 months. Undergo a second surgery at 6 months to have dental implants placed and to evaluate the newly formed bone.
Detailed description
Alveolar ridge resorption following tooth loss frequently results in insufficient bone width or height for ideal dental implant placement, affecting more than 40% of patients seeking implant therapy. Guided Bone Regeneration (GBR) is a well-established surgical technique for reconstructing these deficient ridges using barrier membranes. However, existing membranes present significant limitations: non-resorbable expanded polytetrafluoroethylene (e-PTFE) membranes require a second surgery for removal and carry high exposure-related complication rates, while resorbable collagen membranes often lack adequate mechanical stability and degrade unpredictably, particularly in vertical or large horizontal defects.
The Inox Nanoksa G-Plus membrane is a novel, non-resorbable hybrid nano-ceramic material containing nano-carbon and nano-zirconia within a methacrylate-based high-performance polymer matrix. While the manufacturer claims high strength, wear resistance, and biocompatibility for prosthetic applications, and recent in vitro studies have characterized its mechanical properties, no published clinical study has evaluated its safety or efficacy as a barrier scaffold for GBR in human patients. This knowledge gap forms the basis for the present investigation.
This study is designed as a prospective, single-arm, interventional clinical trial conducted at the Department of Periodontics, Faculty of Dentistry, Cairo University. No randomization or comparator group is included, as this is an initial clinical evaluation of a novel device. All eligible and consenting participants will receive the same standardized intervention.
Study Population: Systemically healthy adult patients (ASA class I or II), aged 18 years or older, presenting with partial edentulism in the maxilla or mandible and requiring horizontal (residual ridge width < 5 mm) or vertical (residual ridge height < 8 mm above vital structures) ridge augmentation prior to dental implant placement. Key exclusions include untreated periodontitis, bisphosphonate therapy, heavy active smoking (>10 cigarettes/day), and pregnancy or lactation.
Intervention: Participants will undergo a single GBR procedure using the Inox Nanoksa G-Plus membrane. The standardized surgical protocol involves a mid-crestal incision with full-thickness flap elevation, cortical perforations to enhance vascularization, placement of a particulate bone graft to fill the defect, and trimming and adaptation of the membrane to extend 3-5 mm beyond the defect margins. The membrane will be secured with titanium micro-screws, and the flap will be closed primarily with a tension-free, double-layer suture technique to achieve complete membrane coverage. Post-operatively, participants will receive prophylactic antibiotics (5-7 days), analgesics, and chlorhexidine mouth rinses for 14 days. Sutures will be removed at 10-14 days.
Study Assessments and Timeline: Participants will be followed for a total of 12 months after implant loading. The primary outcomes (patient-reported) include postoperative pain assessed via a Visual Analog Scale (VAS 0-10), as well as clinical grading of edema and bleeding, recorded on days 1, 3, and 7 post-surgery. Secondary outcomes are assessed clinically and radiographically: membrane exposure (scored 0-3 with descriptive details), infection, graft complications, and radiographic bone gain measured by Cone Beam Computed Tomography (CBCT) at 6 months post-GBR. Horizontal and vertical bone gains will be quantified in millimeters, and new bone density will be measured in Hounsfield Units (HU). At the 6-month re-entry surgery, the membrane and fixation screws will be removed, dental implants will be placed, and implant primary stability will be recorded. A final follow-up at 12 months after implant loading will evaluate implant survival and success.
Data Management and Analysis: All data will be recorded in standardized case report forms and entered into a password-protected electronic database. Statistical analysis will be performed using Medcalc software. Continuous variables will be analyzed using paired t-tests or Wilcoxon signed-rank tests for pre- versus post-operative comparisons, and repeated measures ANOVA for multiple time points. Categorical data will be presented as frequencies and percentages. A p-value ≤ 0.05 will be considered statistically significant. The sample size of 12 participants was calculated to estimate the mean bone gain with adequate precision, accounting for an anticipated 20% dropout rate.
Ethics and Dissemination: The study protocol has received ethical approval from the Research Ethics Committee of the Faculty of Oral and Dental Medicine, Cairo University. All participants will provide written informed consent in Arabic after receiving a full explanation of the procedures, benefits, risks, and alternative treatments. Participant confidentiality will be strictly maintained. The results of this study will be submitted for publication in a peer-reviewed dental journal and presented at academic conferences, regardless of the outcome direction, to contribute evidence on the clinical applicability of synthetic high-performance polymer membranes in bone regeneration.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- All participants receive the same GBR procedure using the Inox Nanoksa G-Plus membrane.
| Arm | Type | Receives |
|---|---|---|
| Nanoksa G-Plus GBR Group | Experimental | Device: Inox Nanoksa G-Plus Membrane, Device: Particulate Bone GraftParticipants with horizontal or vertical alveolar ridge deficiency undergo guided bone regeneration using the Inox Nanoksa G-Plus membrane in conjunction with a particulate bone graft. All participants receive the same standardized surgical protocol. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Partial edentulism in the maxilla or mandible requiring single or multiple implant-supported restorations.
- Insufficient bone volume for standard implant placement, defined as:
- Healthy oral mucosa with no signs of active infection or inflammation at the defect site.
- Systemically healthy or with well-controlled medical conditions (American Society of Anesthesiologists - ASA class I or II).
Key exclusion criteria (5 listed)
- Untreated periodontitis or active peri-implant disease.
- Current or previous treatment with intravenous bisphosphonates (or oral bisphosphonates for > 3 years).
- Severe immunosuppression or chronic systemic corticosteroid therapy (> 10 mg/day prednisolone for > 3 months).
- Active smoking (> 10 cigarettes per day). Smoking cessation for at least 2 weeks before surgery is required; heavy smokers may be excluded.
- Pregnant or lactating women.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Inox Nanoksa G-Plus MembraneA sterile, non-resorbable hybrid nano-ceramic membrane composed of a methacrylate-based high-performance polymer matrix reinforced with nano-zirconia and nano-carbon. It is supplied as a pre-formed sheet (thickness ~0.2-0.3 mm) that can be cut and shaped intraoperatively. The membrane serves as a barrier scaffold to exclude soft tissue cells and allow osteogenic cells to populate the bone defect during guided bone regeneration. | Device | Nanoksa G-Plus GBR Group |
| Particulate Bone GraftA commercially available particulate bone graft material (xenograft, allograft, or synthetic) selected based on defect type and surgeon preference. The graft is hydrated with sterile saline or autologous blood and packed into the defect to fill the volume and provide a scaffold for new bone formation. | Device | Nanoksa G-Plus GBR Group |
Primary outcome
Postoperative Pain
Time frame: Days 1, 3, and 7 post-surgery
Pain intensity measured using a Visual Analog Scale (VAS) where 0 = no pain and 10 = worst imaginable pain. Patients record pain at rest and during function.
Postoperative Edema/Swelling
Time frame: Days 1, 3, and 7 post-surgery
Clinically graded by a blinded assessor using a 4-point scale: 0 = none, 1 = mild (localized, intraoral only), 2 = moderate (visible extraoral swelling, no functional impairment), 3 = severe (significant facial swelling with functional impairment).
Postoperative Bleeding
Time frame: Days 1, 3, and 7 post-surgery
Clinically assessed at the surgical site using a 4-point scale: 0 = none, 1 = mild (oozing, stops spontaneously), 2 = moderate (requires gauze change or local pressure), 3 = severe (requires surgical intervention).
5 secondary outcomes
Horizontal Bone Gain
Time frame: 6 months post-GBR (T2) vs. Baseline (T0)
Vertical Bone Gain
Time frame: 6 months post-GBR (T2) vs. Baseline (T0)
Membrane Exposure
Time frame: Throughout healing period (up to 6 months post-GBR)
New Bone Density
Time frame: 6 months post-GBR (T2) vs. Baseline (T0)
Patient Satisfaction
Time frame: 6 months post-GBR (T2)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Jul 2026.
- Individual participant dataSharing planned: No
Related trials for Alveolar Ridge Deficiency
Not yet recruiting
Autogenous and Xenograft Bone Mix in Alveolar Ridge Reconstruction
Horizontal Alveolar Ridge Deficiency
Not yet recruiting
Comparison of Three Autogenous Bone and Xenograft Ratios for Horizontal Ridge Augmentation
Horizontal Alveolar Ridge Deficiency
Not yet recruiting
Comparison of Two Autogenous Bone and Xenograft Ratios for Horizontal Ridge Augmentation
Horizontal Alveolar Ridge Deficiency
Not yet recruiting
Shell Technique for Implant Site Development
Ridge Augmentation, Ridge Deficiency
Not yet recruiting
Effectiveness of Subepithelial Connective Tissue Graft as an Autogenous Barrier Membrane for Hard and Soft Tissue Augmentation in Horizontally Deficient Ridges During Delayed Implant Placement
Horizontally Deficient Alveolar Ridges, Hard and Soft Tissue Augmentation During Delayed Implant Placement
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Inox Nanoksa G-Plus Membrane and Particulate Bone Graft in people with Alveolar Ridge Deficiency and Alveolar Bone Loss, run by Cairo University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 14 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Hazem A Hazem Ahmed Elsayed (+201099751196, hazem.elsayed@dentistry.cu.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Postoperative Pain (time frame: Days 1, 3, and 7 post-surgery). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Jul 2026.